Özlem Yüksel AKSOY, Oğuz CANAN, Özbay Ferda HOŞNUT, EdaYılmaz AKÇAY, Figen ÖZÇAY

Fecal calprotectin levels in Helicobacter pylori gastritis in children

Background. Fecal calprotectin is an important inflammatory marker in intestinal diseases and is not routinely used in the upper gastrointestinal system disorders. The aim of this study was to show whether there is a relationship between fecal calprotectin levels and Helicobacter pylori (H pylori) gastritis in children and to determine the association of fecal calprotectin levels with gastric biopsy results in terms of chronic inflammation and neutrophil activity. Methods. Patients with the complaints of the upper gastrointestinal system (epigastric pain, heartburn, nausea and vomiting) who were planned to undergo endoscopy were enrolled prospectively. The presence of H pyloriwas defined according to the gastric antrum biopsy results. Fecal calprotectin level was tested in the stool sample of the patients. The fecal calprotectin levels, upper gastrointestinal endoscopy and gastric biopsy results of 89 patients were evaluated. Results. H pylori was found to be positive in the gastric biopsies of 51 (57.3%) patients. In the H pylori positive group mean fecal calprotectin level was 74.8 ± 67 µg/g, and in the H pylori negative group mean fecal calprotectin level was 52.7 ± 46 µg/g and the difference was significant (p= 0.039). We also found a significant relationship between fecal calprotectin levels and gastric neutrophil activity grades (p= 0.034). Conclusions. Mean fecal calprotectin levels were found to be higher in H pylori positive subjects in our study. Fecal calprotectin levels were correlated with gastric neutrophil activity grades. Fecal calprotectin represents gastric neutrophilic inflammation. When interpreting a high fecal calprotectin level, H pylori infection should be kept in mind.

PDF

___

1. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1-241.

2. Roma E, Panayiotou J, Pachoula J, et al. Intrafamilial spread of Helicobacter pylori infection in Greece. J Clin Gastroenterol 2009; 43: 711-715.

3. Pérez-Pérez GI,Sack RB, Reid R, Santosham M, Croll J, Blaser MJ. Transient and persistent Helicobacter pylori colonization in Native American children. J Clin Microbiol 2003; 41: 2401-2407.

4. Ertem D, Harmanci H, Pehlivanoğlu E. Helicobacter pylori infection in Turkish preschool and school children: role of socioeconomic factors and breast feeding. Turk J Pediatr 2003; 45: 114-122.

5. Carvalho MA, Machado NC, Ortolan EV, Rodrigues MA. Upper gastrointestinal histopathological findings in children and adolescents with nonulcer dyspepsia with Helicobacter pylori infection. J Pediatr Gastroenterol Nutr 2012; 55: 523-529.

6. Guarner J, Kalach N, Elitsur Y, Koletzko S. Helicobacter pylori diagnostic tests in children: review of the literature from 1999 to 2009. Eur J Pediatr 2010; 169: 15-25.

7. Drumm B, Koletzko S, Oderda G. Helicobacter pylori infection in children: a consensus statement. European Paediatric Task Force on Helicobacter pylori. J Pediatr Gastroenterol Nutr 2000; 30: 207- 213.

8. Uğraş M, Pehlivanoğlu E. Helicobacter pylori infection and peptic ulcer in eastern Turkish children: is it more common than known? Turk J Pediatr 2011; 53: 632-637.

9. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest 2007; 117: 60-69.

10. Whitney AE, Guarner J, Hutwagner L, Gold BD. Helicobacter pylori gastritis in children and adults: comparative histopathologic study. Ann Diagn Pathol 2000; 4: 279-285.

11. Bedoya A, Garay J, Sanzón F, et al. Histopathology of gastritis in Helicobacter pylori-infected children from populations at high and low gastric cancer risk. Hum Pathol 2003; 34: 206-213.

12. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-1181.

13. Fiocca R, Villani L, Luinetti O, et al. Helicobacter colinization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: a morphological approach to the study of ulcerogenesis in man. Virchows Arch A Pathol Anat Histopathol 1992; 420: 489-498.

14. Stolte M, Eidt S. Chronic erosions of the antral mucosa: a sequela of Helicobacter pylori-induced gastritis. Z Gastroenterol 1992; 30: 846-850.

15. Bjarnason I. The use of fecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2017; 13: 53-56.

16. Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol 2014; 8: 197-210.

17. Montalto M, Gallo A, Ianiro G, et al. Can chronic gastritis cause an increase in fecal calprotectin concentrations? World J Gastroenterol 2010; 16: 3406-3410.

18. Sýkora J, Huml M, Siala K, et al. Paediatric Rome III criteria-related abdominal pain is associated with Helicobacter pylori and not with calprotectin. J Pediatr Gastroenterol Nutr 2016; 63: 417-422. 19. Ezri J, Nydegger A. Pediatrics. Fecal calprotectin in children: use and interpretation. Rev Med Suisse 2011; 7: 69-70.

20. Kostakis ID, Cholidou KG, Vaiopoulos AG, Vlachos IS, Perrea D, Vaos G. Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review. Dig Dis Sci 2013; 58: 309-319.

21. Lobatón T, Rodríguez-Moranta F, Lopez A, Sánchez E, Rodríguez-Alonso L, Guardiola J.A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis 2013; 19: 1034-1042.

22. Mišak Z, Hojsak I, Homan M. Review: Helicobacter pylori in pediatrics. Helicobacter 2019; 24(Suppl 1): e12639.

23. Ünlüsoy Aksu A, Yılmaz G, Eğritaş Gürkan Ö, Sarı S, Dalgıç B. The effect of Helicobacter pylori eradication on functional dyspepsia in Turkish children. Helicobacter 2018; 23: e12497.

24. Yu Y, Su L, Wang X, Wang X, Xu C. Association between Helicobacter pylori infection and pathological changes in the gastric mucosa in Chinese children. Intern Med 2014; 53: 83-88.

25. Flagstadt G, Helgeland H, Markestad T. Faecal calprotectin concentration in children with functional gastrointestinal disorders diagnosed according to pediatric Rome III criteria. Acta Pediatr 2010; 99: 734-737.

26. Lahat A, Kopylov U, Neuman S, et al; on behalf of the Israeli IBD research Network (IIRN) Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn’s disease. BMC Gastroenterol 2017; 17: 27.

27. Summerton CB, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002; 14: 841-845